Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT1013 versus cinacalcet in secondary hyperparathyroidism on dialysis
NCT07122401Phase 3Recruiting
- Sponsor
- Shaanxi Micot Technology Co., Ltd.
- Start
- Sep 2025
- Primary completion
- Nov 2026
- Modality
- Recombinant Proteins and Enzymes, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of MT1013 in secondary hyperparathyroidism (SHPT), sponsored by Shaanxi Micot Technology Co., Ltd.. Started Sep 2025; status: recruiting.
02
Drugs
MT1013
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT07122401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07122401.